Organic Active Ingredients TRIZ Cases

Optimized PM14 administration schedules resolve the contradiction between treatment efficacy and side effects in renal cancer and melanoma therapies.

Substituted oxadiazoles inhibit USP28 by mimicking catalytic triad interactions, resolving low selectivity in DUB inhibitor development.

Combining fatty acid synthase inhibitors with paclitaxel overcomes drug resistance in metastatic tumors.

Tetrahydropyrrolothiazine compounds inhibit beta-secretase to lower amyloid beta levels, addressing transient symptomatic relief in Alzheimer's disease.

A tacky biocompatible polymer film releases bioactive agents from implant surfaces.

Phosphorothioate linkages enhance metabolic stability, resolving the trade-off between therapeutic efficacy and off-target effects in hepatitis B treatment.

Spiro-oxindole compounds undergo asymmetric synthesis using chiral phase transfer catalysts to achieve high enantiomeric purity.

A zinc prodrug composition enables targeted delivery of therapeutic agents to beta cells through selective enzymatic activation.

siRNA oligonucleotides silence PLP1 mRNA to reverse neurological damage while avoiding the complexity of targeted delivery systems.

Topical CpG oligonucleotide and imidazoquinoline composition stimulates innate immune response to accelerate wound repair.

Modified chemical structures enhance stability and bioavailability of nicotinamide riboside derivatives to treat mitochondrial diseases.

Topical imidazole compounds modulate immune responses, reducing inflammation and adverse side effects in skin treatments.

Codon-optimized plasmid DNA encoding mutant ErbB-3 overcomes resistance mechanisms mediated by HER3, enhancing therapeutic efficacy in cancer treatment.

Thioether triazolopyridine compounds inhibit myeloperoxidase activity to preserve heart function.

Measuring CD133 expression detects resistance to EGFR-targeting agents in colon cancer, enabling targeted therapy selection.

Topical alpha-1 adrenergic receptor agonists applied to the nipple-areola complex trigger smooth muscle contraction and endogenous oxytocin release.

Extended-release trihexyphenidyl composition uses an organic acid core to enhance drug solubility and maintain therapeutic plasma levels.

A liposome formulation encapsulates irinotecan using a specific phospholipid and cholesterol ratio to maintain drug stability.

Thienopyrimidine compounds block menin binding to MLL fusion proteins, reducing leukemogenic potential in acute leukemia.

Aptamer conjugates bind EpCAM and transferrin receptors to cross the blood-brain barrier.

Benzothiophene compound activates IK1 channels, addressing the lack of effective agents for visceral and neuropathic pain treatment.

Neutral polysaccharide with alpha-1,4-glycosidic bonds prevents cancer cell nidation in abdominal cavities.

Engineered allogeneic T-cells withstand chemotherapeutic agents through targeted gene inactivation.

Specific crystallization conditions produce stable polymorph forms that resolve manufacturing consistency issues while ensuring therapeutic effectiveness.

Galactomannan polysaccharide thickening reduces laryngeal vestibule closure time and swallowing response duration.

Buffered vaginal gel merges metronidazole and terconazole to treat bacterial vaginosis and vulvovaginal candidiasis co-infections.

6-Heteroaryloxy-quinoline-2-carboxamides selectively block Nav 1.7 and Nav 1.8 channels.

Intraperitoneal polycationic polymers bind anionic glycosaminoglycans in visceral adipose tissue, reducing fat mass while sparing off-target organs.

A crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride form with defined X-ray diffraction angles and a melting point of 134.25 ± 3°C.

Serum exosomal SF3B4 marker composition delivers high diagnostic accuracy for early stage hepatocellular carcinoma without invasive tissue biopsy.

Hydrazone compounds selectively bind CB2 receptors to relieve neuropathic pain while avoiding psychoactive CNS side effects.

Anti-LIF neutralizing antibodies constrain the JAK-STAT signaling pathway to reduce tumor proliferation while sparing healthy tissue from adverse side effects.

A novel lipid compound with optimized hydrocarbon groups enables high nucleic acid encapsulation rates in delivery carriers.

Substituted ZT-1A analogs inhibit SPAK kinase function to prevent white matter disruption in neurodegenerative disorders.

Nenitzescu reaction couples quinonimine and enaminone intermediates, eliminating hazardous reagents and metal salt waste from traditional synthesis routes.

Guide RNA recognizes unique STAT1 SNPs to selectively knockout dominant-mutated alleles while preserving functional protein expression.

Formula A and I compounds selectively inhibit HER2 and EGFR kinases, halting acquired resistance while reducing side effects from non-specific targeting.

Integrates selenium-enriched yeast, N-acetylcysteine, and zinc gluconate to overcome the limitation of single-effect drugs.

A liposome carrier co-loads STING agonists and ENPP1 inhibitors to enhance anti-tumor activity.

Modular synthesis of 6,7-dialkoxynaphtho[2,3-c]furan-1(3H)-one derivatives resolves manufacturing cost barriers while delivering targeted antiviral efficacy.

Azabicycloalkane-substituted pyridone derivatives activate the alpha7 nicotinic acetylcholine receptor to enhance cognitive functions.

miR4689 targets KRAS and AKT1 genes via carbonate apatite delivery to overcome anti-EGFR resistance in KRAS-mutant cases.

Segmented synthesis of dolutegravir generates novel intermediates through distinct reaction stages, resolving low efficiency and lack of new compounds.

APC activators restore defective anaphase promoting complex function, reducing drug resistance and sensitizing cancer cells to chemotherapy.

Targeted enzyme inhibition modulates PKM2 nitrosylation to divert glucose flux, alleviating oxidative stress and treating acute kidney injury.